# SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging

> **NIH NIH U24** · UNIVERSITY OF CALIFORNIA BERKELEY · 2021 · $641,593

## Abstract

PROJECT SUMMARY
Amyloid PET is central to a biological definition of Alzheimer’s disease (AD) and has been integrated heavily into
the research setting since the first PIB-PET scans in 2004. The SCAN-Amyloid Legacy (SCAN-AL) Project
will leverage already established research programs (SCAN, NACC, LONI) along with extensive work that has
been conducted over the previous 15 years at the ADRC site level to implement and collect expensive and
valuable amyloid PET data on ADRC research participants. The ultimate goal of this effort is to curate and
harmonize pre-existing amyloid PET data collected across ADRC sites to create a large-scale resource
that can be disseminated to the ADRC community for use in various research endeavors. More
specifically, during this award period we will aim to curate 3000 amyloid PET scans, which is similar to the
number of amyloid PET scans currently available through ADNI, and to link this data to extensive data already
available on these participants (clinical and cognitive data, biofluid data, postmortem data, etc). Whereas the
parent SCAN award focuses on processing of prospective PET and MRI data utilizing rigorous standardization
methods both during image acquisition and post-acquisition processing, SCAN-AL will allow more flexibility to
enable the specific goal of obtaining legacy amyloid PET data on as many unique ADRC Clinical Core
participants as possible. This work is significant because we are quickly approaching 2025 and still lack a
disease modifying treatment for AD. The data leveraging proposed herein extends the value of the
considerable funding has been directed towards cohort studies of AD to contribute towards this goal of
curing AD by 2025. Increasing the utilization of pre-existing amyloid PET dataset across ADRCs is particularly
significant and unique compared to other large-scale efforts such as ADNI, given the heterogeneity in ADRC
participants both in terms of clinical diagnoses and demographics. Whereas ADNI focuses specifically on normal
aging, mild cognitive impairment (MCI), and AD diagnoses, the ADRC program recruits participants spanning a
range of neurodegenerative diseases that reflect the focus and expertise of local investigators, such as vascular
disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Parkinson’s, etc.
Further, the ADRC program is unique in that a broad range of demographics regarding race, ethnicity, and age
are reflected. We anticipate that the SCAN-AL Project will contribute to timely scientific opportunities related to
the validation of plasma AD biomarkers, support innovative analyses that require large datasets such as work
with genetics and machine learning, as well as enable the investigation of rare phenotypes that are difficult to
collect at one site alone. This effort will provide ample opportunities to AD investigators and complement the
efforts of the SCAN initiative.

## Key facts

- **NIH application ID:** 10335694
- **Project number:** 3U24AG067418-02S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA BERKELEY
- **Principal Investigator:** CLIFFORD R. JACK
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $641,593
- **Award type:** 3
- **Project period:** 2020-05-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10335694

## Citation

> US National Institutes of Health, RePORTER application 10335694, SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging (3U24AG067418-02S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10335694. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*